TORONTO, May 4, 2012 /CNW/ - Pharmacogenetics (personalized medicine) will help doctors better prescribe medicine to patients who carry specific genes which put them at risk for serious side-effects.
|Who:||Larry Tanenbaum, Chair of the Board for Maple Leaf Sports and Entertainment, CEO and Chair of the Kilmer Group and a Governor of the NHL, NBA and MLS|
|The Honourable Brad Duguid, Minister of Economic Development and Innovation|
|Dr. James Kennedy, Director of the Neuroscience Research Department and Head of the Psychiatric Neurogenetics Section, CAMH|
|Dr. Catherine Zahn, President and CEO, CAMH|
|| Monday, May 7, 2010
|Where:||CAMH Research Imaging Centre, 250 College Street, Basement|
Tours of the pharmacogenetics laboratory will be available following the announcement
The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health and addiction teaching hospital, as well as one of the world's leading research centres in the area of addiction and mental health. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental health and addiction issues.
CAMH is fully affiliated with the University of Toronto, and is a Pan American Health Organization/World Health Organization Collaborating Centre.
For further information:
Media Contact: Michael Torres, Media Relations, CAMH; 416-595-6015; firstname.lastname@example.org